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Background:  Inflammatory or thrombotic biomarkers may help to identify pts at high risk to develop stent thrombosis (ST) in pts with STEMI 
treated with primary PCI and stent implantation.
Methods:  23 inflammatory-thrombotic biomarkers were measured at admission and just prior to discharge in 502 STEMI pts in a formal substudy 
of the HORIZONS-AMI trial and analyzed in a central core laboratory. All pts underwent primary PCI with TAXUS paclitaxel-eluting stents. We divided 
pts in tertiles based on biomarker levels and explored associations between biomarkers and ARC definite/probable ST. For biomarkers measured at 
discharge, only out-of hospital events were analyzed.
Results:  The 3-year definite/probable ST rate was 4.1% (n=19), and 0.4% (n=1) of ST cases occurred in-hospital. Low Interleukin 18 (IL-18) 
and high pro-atrial natriuretic peptide (pro-ANP) measured at adomission were associated with the incidence of definite/probable ST at 3 years. 
Moreover, the increase in IL-18 from admission to discharge and high myeloperoxidase (MPO) measured at discharge were predictive of ST up to 
3-year follow-up. CRP and BNP were not found to be predictive of ST. Multivariate analysis models will be available at time of presentation.
Conclusion: Low IL-18 and high pro-ANP measured at admission, a high MPO at discharge, and an increase in IL-18 plasma concentration 
between admission and discharge were associated with 3-year ST. These findings should be validated in prospective studies. 
